CONTENTS

BRAINSTORMS
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors
Stephen M. Stahl 305

EDITORIAL
The surprising blindness in modern psychiatry: do guidelines really guide?
Pedro Antônio Schmidt do Prado-Lima 312

ORIGINAL RESEARCH
Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis
Jordi Espadañer, Miguel Tuset, Jose Miguel Lopez-Ibor, Francisco Lopez-Ibor and Maria Ines Lopez-Ibor 315

Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity
Bernardo Dell’Osso, Cristina Dobrea, Laura Cremaschi, Massimiliano Buoli, Sh elitai Miller, Terence A. Ketter and A. Carlo Altamura 325

Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kiley, Linda Snow-Adami, Roger S. McIntyre, Maju Mathews and Carla Hundt 333

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
Domenico De Berardis, Michele Fornaro, Laura Orsolini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomei, Nicolina Tomassetti, Ida De Laurenti, Gabriella Ginnelli, Monica Mazzu, Alessandro Vechtnei, Alessandro Cerano, Federica Vellante, Ilaria Matarazzo, Giampaolo Perna, Giovanni Martini and Massimo Di Giannantonio 342

Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis
Jordi Espadañer, Miguel Tuset, Jose Miguel Lopez-Ibor, Francisco Lopez-Ibor and Maria Ines Lopez-Ibor 315

Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity
Bernardo Dell’Osso, Cristina Dobrea, Laura Cremaschi, Massimiliano Buoli, Sh elitai Miller, Terence A. Ketter and A. Carlo Altamura 325

Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kiley, Linda Snow-Adami, Roger S. McIntyre, Maju Mathews and Carla Hundt 333

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
Domenico De Berardis, Michele Fornaro, Laura Orsolini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomei, Nicolina Tomassetti, Ida De Laurenti, Gabriella Ginnelli, Monica Mazzu, Alessandro Vechtnei, Alessandro Cerano, Federica Vellante, Ilaria Matarazzo, Giampaolo Perna, Giovanni Martini and Massimo Di Giannantonio 342

Cambridge Core
For further information about this journal please go to the journal web site at: cambridge.org/cns
Want some CME with that?

STAHLMARTERCALASS

• An online educational program in core areas of psychiatry with interactive readings, short lectures, animations and case studies
• Self-testing and opportunities to claim formal CME credits, all taken at a self-directed speed
• Written and moderated by experts in the field from the Dr. Stahl’s Neuroscience Education Institute and the University of Cambridge

For more information, please go to www.stahlmasterclass.com

NEI MEMBERSHIP
COMBINING PRACTICAL EDUCATION WITH PRACTICE-BASED TOOLS

Unlock the value of NEI Membership today!
Take advantage of valuable online resources, receive free CME credits, and enjoy big discounts on live and online programs—all designed to keep you up-to-date in your clinical practice.

12-Month Membership includes:
• NEW! NEI Prescribe app
• Master Psychopharmacology Program access
• This Month in Psychopharmacology—psychiatric news updates
• Maintenance of Certification (MOC) Self-Assessment activities
• CNS Spectrums journal—online subscription
• Online versions of The Prescriber’s Guide series
• Patient education and teaching materials

Member Benefit Spotlight—NEI Prescribe app
The most powerful tool for your prescribing arsenal is here!
» 130+ psychotropic medications
» Expert Tips and Pearls
» Unique Filter to identify alternative medication options
Included with NEI membership! Not yet a Member?
Download NEI Prescribe for a free 3-month trial!

Join today for only $219, normally $249!
Use promo code: 16CNS$30

www.neiglobal.com | (888) 535.5600
BRAINSTORMS

Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors
Stephen M. Stahl 305

EDITORIAL

The surprising blindness in modern psychiatry: do guidelines really guide?
Pedro Antônio Schmidt do Prado-Lima 312

ORIGINAL RESEARCH

Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis
Jordi Espadaler, Miquel Tuson, Jose Miguel Lopez-Ibor, Francisco Lopez-Ibor and Maria Ines Lopez-Ibor 315

Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity
Bernardo Dell’Osso, Cristina Dobrea, Laura Cremaschi, Massimiliano Buoli, Shefali Miller, Terence A. Ketter and A. Carlo Altamura 325

Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kelly, Linda Snow-Adami, Roger S. McIntyre, Maju Mathews and Carla Hundt 333

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
Domenico De Berardis, Michele Fornaro, Laura Orsolini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomeis, Nicola Serroni, Ida De Lauretis, Gabriella Girinelli, Monica Mazza, Alessandro Valchera, Alessandro Carano, Federica Vellante, Ilaria Matarazzo, Giampaolo Perna, Giovanni Martinotti and Massimo Di Giannantonio 342

Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older
George G. Nomikos, Dapo Tomori, Wei Zhong, John Affinito and William Palo 348

Posttraumatic stress disorder symptom severity is associated with left hippocampal volume reduction: a meta-analytic study
Michael D. Nelson and Alecia M. Tumpap 363

CORRIGENDA

Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension—CORRIGENDUM
Joseph F. Goldberg, Daisy Ng-Mak, Cynthia Siu, Chien-Chia Chuang, Krithika Rajagopalan and Antony Loebel 373

The following abstracts were presented as posters at the 2016 NEI Psychopharmacology Congress – CORRIGENDUM

https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852917000487
Aims and Scope

CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to CNS Spectrums

All submissions to CNS Spectrums should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated CNS Spectrums ScholarOne Manuscripts website: http://mc.manuscriptcentral.com/cnsspectr

CNS Spectrums will consider and encourage the following types of articles for publication: Reviews—The review article is a comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; Perspectives—The perspective article is a type of review that is a short, focused summary of a single recent advance, a sort of spotlight on the topic, which could be for example, a single point hypothesis or a novel model. It can stimulate debate and new research. Meta-guidelines—A meta-guideline is a “guideline of guidelines” put together by several leading figures in a field in which there are multiple competing guidelines that require synthesis and updating; Original Research—Reports the results of a clinical study and contains original research; the journal will also include Brainstorms and Editorials that shall be commissioned or written by the Editor-in-Chief.

Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: http://journals.cambridge.org/CNSifc

Indexing

CNS Spectrums is indexed by Index Medicus/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions

Institutional print and electronic: £598/$948; Institutional electronic only: £454/$726.

© Cambridge University Press 2017. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: http://www.cambridge.org/rights/permissions/permission.htm. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center http://www.copyright.com, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking “Request Permissions” within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

CNS Spectrums (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster


Online availability

CNS Spectrums is hosted on the Cambridge Core service at cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: http://journals.cambridge.org/

Reprint and Advertising Sales

Inquiries for bulk reprint sales should be sent to USReprints@cambridge.org. Advertising inquiries should be sent to M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0064; Email: mjmrvica@mrvica.com.